You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Minimal Residual Disease Testing in Acute Leukemia

Version: N/A ID: GL MOTAC-6 Mar 2020
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
M. Sabloff, H. Feilotter, D. Sivajohanathan, C. Howlett, C. Ross, A. Schuh, A. Pollett, and the Minimal Residual Disease Testing Guideline Development Group

Guideline Objective:

To provide evidence surrounding the clinical utility of minimal/measurable residual disease (MRD) testing using multiparameter flow cytometry (MFC), next-generation sequencing (NGS), or polymerase chain reaction (PCR)-based methods in patients with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

Patient Population:

Adult patients with a diagnosis of acute leukemia (i.e., AML or ALL).

Intended Guideline Users:

This guideline is targeted for:

  • Clinicians, laboratory physicians, and scientists involved in the care and testing of patients with acute leukemia.
  • Policy makers, health care administrators, and the Ontario Ministry of Health.

Research Questions:

  1. What benefit to clinical management does MRD testing contribute in the treatment of patients with ALL?
    1. If positive at a certain time point, does a change in treatment alter patient outcomes?
    2. If positive before transplant, does a delay in stem cell transplant and change in treatment, to achieve MRD negativity, alter patient outcomes?
    3. If positive before transplant and negativity is achieved, are patient outcomes different?
  2. What benefit to clinical management does MRD testing contribute in the treatment of patients with AML?
    1. If positive at a certain time point, does change in treatment alter patient outcomes?
    2. If positive before transplant, does a delay in stem cell transplant and change in treatment, to achieve MRD negativity, alter patient outcomes?
    3. If positive before transplant and negativity is achieved, are patient outcomes different?

 

pdf download Summary (PDF) (140.35 KB)
pdf download Full Report (PDF) (714.73 KB)